Funding profile · Consumer preventive health

Lucis

A French SAS that has reported about $28 million raised in two rounds inside five months, with no matching SEC Form D on file. Here is what the corporate registry and the press releases show, and where they do not quite line up.

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

No Form D notice for “Lucis,” “Maxes Company” or the SIREN 927853952 entity appears in SEC EDGAR’s company or full-text search as of September 25, 2026. That is not unusual: Lucis is a French SAS, and Form D is a US filing tied to Regulation D offerings involving US jurisdictional means or sales to US persons. A French company raising in euros from a mix of French, other-European and Silicon Valley-adjacent funds is not required to file one simply because a US-based fund like Y Combinator writes a check. What exists instead is the French corporate registry record, summarized below.

Reading the record

1. No US securities filing exists.A search of SEC EDGAR by company name and by full text turns up nothing for Lucis or its prior name. That is expected for a French issuer raising mostly from non-US-registered vehicles, but it means the round sizes rest entirely on press releases rather than a sworn federal filing.
2. Registered capital is nominal.The RCS lists €1,123.20 in share capital even after roughly $28 million in reported funding. That gap is normal for a French SAS, since invested cash typically sits in share premium, but it also means the registry cannot verify the funding totals independently.
3. The entity predates the brand.Y Combinator’s page says Lucis was “founded 2025,” but the legal entity was registered April 30, 2024, as Maxes Company, and a company database separately describes Lucis as operating “formerly” as Zero Health. The 2025 date likely marks the product launch, not the incorporation.
4. Even the independent press disagrees on the Series A euro figure.EU-Startups’ own headline states €17.3 million while its article body states €17.1 million for the same $20 million round, an unreconciled discrepancy in one outlet’s coverage.
5. A board departure landed just before the raise was announced.The registry shows co-founder Max Guérois’s exit as director general in a filing dated April 24, 2026, roughly a month before the Series A. Some outlets covering the Series A name only two co-founders, while the Y Combinator page and December 2025 coverage name three.

Commercial signals

What to watch

• Whether Lucis or a US-side vehicle ever files a Form D, which would give an independently verifiable dollar figure for a future round.
• Publication of the fiscal 2025 accounts deposited under confidentiality in May 2026, if that confidentiality lapses or a later filing discloses figures.
• Whether Max Guérois’s departure as director general reflects a full exit from the company or a governance restructuring ahead of the Series A.
• Confirmation of the planned Spain, Germany and Italy launches by the end of 2026.

The Lucis story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Breathe Well-being: Shared investor: General Catalyst. A New Delhi area program that coaches people with Type 2 diabetes off medication by phone and through a mobile app
• Finni Health: Shared investor: General Catalyst. A platform that helps board certified behavior analysts open and run their own applied behavior analysis practices, pitched against the private equity chains that bought
• Ophelia: Shared investor: General Catalyst. A telehealth medical practice treating opioid use disorder with medication and a care team
• Maia: Shared investor: North South Ventures. A mobile app that chats and talks with couples together, pitched as an always on stand in for inaccessible couples therapy

Sources

1. Public recordSociété LUCIS (927853952): SIREN, RCS, BODACC filing historyPappers.fr · accessed Sep 25, 2026
2. Public recordLucis SAS, Paris, Siren 927853952North Data · accessed Sep 25, 2026
3. Public recordCompany search and full-text search for “Lucis” and “Maxes Company”SEC EDGAR · Sep 25, 2026
4. IndependentParis preventive-health startup Lucis raises $20M Series A four months after seedTNW, Ana-Maria Stanciuc · May 26, 2026
5. IndependentYC-backed French preventive health platform Lucis raises €17.3 million Series A led by SingularEU-Startups, Rahul Raj · May 26, 2026
6. IndependentLucis lands $20M Series A to expand its AI-driven preventive health platform across EuropeVestbee, Joy Laoun · May 26, 2026
7. IndependentFrench preventive healthcare startup Lucis raises €7.2 million from General Catalyst, Y Combinator, othersEU-Startups, Rahul Raj · Dec 16, 2025
8. IndependentFrench startup Lucis raises $8.5M to expand preventive healthcare across EuropeVestbee, Joy Laoun · Dec 16, 2025
9. IndependentYC-backed Lucis bags $8.5M to turn blood tests into Europe’s daily health dashboardTech Funding News, Vignesh R · Dec 16, 2025
10. IndependentLucis lève 7,2 M€ pour devenir la Function Health européenneUclic, Wladimir Delcros and Alexis Christine-Amara · Dec 22, 2025
11. IndependentLucis (private company), formerly Zero HealthNordic9 · accessed Sep 25, 2026
12. IndependentLucis vs Zoï: quel bilan choisir en 2026Versus.care · Jul 3, 2026
13. CompanyLucis: Function Health for Europe, company profileY Combinator · accessed Sep 25, 2026
14. CompanyLucis raises $20M to make preventive health the standard across EuropeLucis company blog · May 26, 2026

Compiled from the French corporate registry (RCS/BODACC via Pappers.fr and North Data), SEC EDGAR and published reports as of September 25, 2026. Form D notices, where they exist, report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Lucis. This page is not an offer to sell or a recommendation to buy any security.